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Enterobacteria contribute to two serious clinical syndromes
seen in African AIDS patients: diarrhea and septicemia. In West
Africa, prophylaxis with sulfamethoxazole-trimethoprim (SXT)
reduced illnesses. We report reduced sensitivity of enterobacte-
ria to available antimicrobial agents in Zambia, with only 22% of
nontyphoidal salmonellae and 6% of shigellae sensitive to SXT.
iarrhea and septicemia, two of the most important clini-
cal problems of African AIDS patients, are both associ-
ated with high rates of illness and death. Treatment with
antimicrobial agents may play an important role in reducing ill-
ness and possibly death. Chemoprophylaxis (for example, with
cotrimoxazole or sulfamethoxazole-trimethoprim [SXT]) has
been shown to be effective in reducing illness and death (1,2).
The evidence base relating to patterns of antimicrobial resis-
tance in Africa is small, and antimicrobial agents are often cho-
sen on the basis of availability and expense. Some evidence
indicates that resistance patterns vary across Africa, with resis-
tance to SXT in nontyphoidal salmonellae of 14% in Abidjan
and 83% in Malawi (3). We report the prevalence of infection
with three major enterobacteria in Zambian adults and children
with AIDS, followed by an analysis of antimicrobial sensitivity
patterns. 
The Study
To determine the prevalence of infection in adults and chil-
dren, cultures were performed by standard techniques on fecal
samples from several groups of adults and children, all resi-
dents of Lusaka, the capital of Zambia. Group A was 124
adults and 105 children, all HIV-seropositive patients with per-
sistent diarrhea, studied from 1995 to 1999 during three clini-
cal trials of antiprotozoal or nutritional therapies. The average
number of samples tested was 2.1 for each adult and 2.8 for
each child. Group B was 216 adults enrolled in a longitudinal
study of intestinal infection in a cohort of adults in a represen-
tative urban community in Lusaka; this group was studied to
provide an estimate of asymptomatic carriage rates. 
To define the profile of antimicrobial sensitivity, isolates
from Group A were analyzed together with additional isolates
of nontyphoidal salmonellae, Shigella dysenteriae, and S. flex-
neri from a third source (Group C): routine stool or blood cul-
tures from AIDS patients in the University Teaching Hospital
from 1995 to 1999. All isolates were cultured and tested for
antimicrobial susceptibility by using standard antimicrobial
discs (Oxoid Ltd, Basingstoke, UK) on Mueller-Hinton agar.
Zones of growth inhibition were compared with standard tables
(4), and control organisms of known sensitivity were tested
beside clinical isolates for verification.
Of 124 adults with persistent diarrhea in Group A, 6 (5%)
were infected with nontyphoidal Salmonella spp. and 9 (7%)
with S. flexneri or S. dysenteriae. Of 105 children with persis-
tent diarrhea, also in Group A, 21 (20%) were infected with
nontyphoidal Salmonella spp. and 3 (3%) with S. flexneri or S.
dysenteriae. In Group B, 7 (4%) of 174 adults had one or more
fecal samples positive for nontyphoidal Salmonella spp. in one
year (1999), and 10 (6%) had one or more positive for S. flex-
neri  or S. dysenteriae. As each adult submitted samples
approximately monthly (for a total of 1,440 samples), the point
prevalence in these asymptomatic adults was <1% for either
infection. 
Studies of patients with HIV-related persistent diarrhea in
other countries in Africa have found the prevalence of entero-
bacterial infection to be higher. In Rwanda and Kenya, preva-
lences of nontyphoidal salmonellae were 11% and 16%,
respectively, and of shigellae were 22% and 4%, respectively
(5,6). In recent years, HIV seroprevalence in Lusaka has been
estimated to be 22% to 30% (7), and the overall rate of HIV-
related diarrhea is high (8).
Conclusions
Antimicrobial sensitivity patterns indicate that resistance is
a substantial problem among enterobacteria in Lusaka (Table).
The isolates we tested came from a tertiary hospital, which
may have resulted in some selection bias, as treatment failures
may be overrepresented in such patients. However, only a few
bacteria tested were sensitive to SXT, in marked contrast to
data from West Africa and more closely resembling the situa-
tion in Malawi (3). This level of resistance may compromise
the usefulness of SXT in preventing bacterial infection in HIV-
infected persons, although any effect in preventing  Pneu-
mocystis carinii pneumonia or isosporiasis would be valuable.
Emergence of resistance to SXT was noted in San Francisco
after its widespread use as prophylaxis against pneumocystosis
(9). For treatment of infection with these enterobacteria in
Zambia, only the more expensive antimicrobial agents now
seem to be reliable. Providing effective, affordable parenteral
antimicrobial agents for the efficient treatment of septicemic
infection in hospitals and health centers is likely to be difficult.
As clinical response sometimes occurs even when susceptibil-
ity testing in vitro suggests that the antimicrobial agent used is
ineffective, controlled clinical trials are needed for these infec-
tions in different geographic regions of Africa.
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DISPATCHES
Antimicrobial sensitivity appeared to decrease from 1995
to 1999, when these isolates were being collected. For exam-
ple, over this period gentamicin resistance increased from 0%
to 32% in S. flexneri and from 0% to 34% in nontyphoidal sal-
monellae (p<0.001). In  S. flexneri, cefuroxime resistance
increased from 22% to 88% and cephalexin resistance from
18% to 42% over the same period (p = 0.001). The scale of use
of cephalosporins in the community did not suggest that selec-
tion pressure for resistance was likely to be high. Mechanisms
of resistance to cephalosporins include reduced permeability
and modification of penicillin-binding protein, and emergence
appears to be rapid.
Which antimicrobial agents could be recommended for
treatment of bacteremic nontyphoidal salmonellosis? The most
reliable results are likely to be obtained with fluoroquinolones
or azithromycin, but these are expensive and their availability
is limited. Gentamicin or chloramphenicol are less expensive
and would be acceptable alternatives, although the probability
of adverse effects is greater. Unfortunately, few antimicrobial
compounds that are likely to be effective and affordable could
also be given easily and safely to AIDS patients in primary and
secondary care settings in Zambia. As the epidemic in Zambia
enters its third decade, the situation is likely to worsen if no
action is taken. We have been able to reduce antimicrobial
resistance in Vibrio cholerae by instituting a policy of rotating
the recommended antimicrobial agents during epidemics,
thereby prolonging the useful life of affordable antimicrobial
agents (J. Mwansa, unpub. obs.). This strategy could be
extended to enterobacterial infection in AIDS. We are also
considering clinical trials with combinations of antimicrobial
drugs to treat these clinical syndromes in AIDS patients. As
antimicrobial sensitivity patterns seem to vary across Africa, it
may be difficult to generalize the results of clinical trials from
one part of the continent to another.
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Table. Summary of antimicrobial sensitivity patterns for three










Tetracycline 37 (6) 2 (6) 3 (16)
Chloramphenicol 36 (77) 7 (22) 8 (48)
Gentamicin 119 (75) 24 (77) 18 (95)
Sulphamethoxazole-
trimethoprim
25 (22) 3 (10) 0 (0)
Amoxycillin 74 (48) 9 (30) 7 (37)
Amoxycillin-
clavulanic acid
95 (60) 27 (87) 12 (63)
Cephalexin 105 (66) 23 (74) 17 (89)
Cefuroxime 93 (59) 11 (35) 16 (74)
Cefotaxime 149 (88) 28 (90) 19 (95)
Nalidixic acid 107 (67) 31 (100) 19 (100)
Ciprofloxacin 157 (99) 30 (97) 18 (95)
Erythromycin 22 (14) 0 (0) 4 (21)
Azithromycin 64 (92) 9 (100) 19 (100)
a158 isolates of nontyphoidal salmonellae, 31 isolates of S. flexneri, and 19 isolates of
S. dysenteriae were tested against all these antimicrobial agents except for
azithromycin, against which 69, 9, and 19 isolates were tested respectively.